• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Marie Powers

Marie Powers

Articles

ARTICLES

Straight Aro: Ex-J&J execs move Centyrin platform into oncology, immunology

Dec. 12, 2018
By Marie Powers
Johnson & Johnson (J&J) placed its trust in the future of Centyrin technology into familiar hands at Aro Biotherapeutics Co., a startup co-founded by two former J&J executives, including the co-inventor on the Centyrin patents.
Read More

Revance broadens target on Allergan's back with Fosun deal, phase III aesthetic data

Dec. 12, 2018
By Marie Powers
Revance Therapeutics Inc. has never made a secret of its goal to build a better Botox. The Newark, Calif.-based company is making swift progress to reach that target as it prepares to file a BLA for lead program RT-002, an injectable formulation of daxibotulinumtoxinA, in moderate to severe glabellar lines after moving RT-002 into a pivotal phase III to treat cervical dystonia.
Read More

Asana on fast track in atopic dermatitis with first dual JAK/SYK inhibitor

Dec. 11, 2018
By Marie Powers
Asana Biosciences LLC was the first to move a dual Janus kinase (JAK) and spleen tyrosine kinase (SYK) inhibitor into the clinic in moderate to severe atopic dermatitis. The company has been rewarded for the effort with an FDA fast track designation for lead candidate ASN-002, which is under investigation in the phase IIb RADIANT (Relief from Atopic DermatitIs with JAK and SYK INhibiTion) study. Asana also is evaluating ASN-002 in a phase II study in individuals with severe chronic hand eczema.
Read More

Moderna goes out big(ger) as biopharma wrings 3 more IPOs from wobbly market

Dec. 10, 2018
By Marie Powers
Diamedica Therapeutics Inc., a phase II biopharma targeting acute ischemic stroke and chronic kidney disease, completed its micro-IPO, raising $16.4 million by offering 4.1 million shares at $4, the low end of its proposed range. Synthorx Inc. went bigger, hauling in $131 million by offering 11.9 million shares at $11, the midpoint of its proposed $10 to $12 range.
Read More

Millendo moves to Nasdaq courtesy Ovascience reverse merger, picks up $49.5M more

Dec. 10, 2018
By Marie Powers
Despite a handful of last-minute lawsuits seeking to halt the proceedings, shareholders of Ovascience Inc. gave their endorsement Dec. 4 to the reverse merger with Millendo Therapeutics Inc. Shares of the combined company, operating under the Millendo name, are expected to begin trading on the Nasdaq Capital Market Monday under the ticker MLND.
Read More

Xylocor strikes chord in CAD, lands $17M series A for gene therapy bid

Dec. 7, 2018
By Marie Powers
Four years out from opening its doors, Xylocor Therapeutics Inc. closed a $17 million series A as it prepared to move lead candidate XC-001, a cardiovascular angiogenic gene therapy, into phase I in individuals with refractory angina who have no other treatment options. The round was co-led by Sofinnova Ventures and LSP (Life Sciences Partners).
Read More

Revance broadens target on Allergan's back with Fosun deal, phase III aesthetic data

Dec. 5, 2018
By Marie Powers
Revance Therapeutics Inc. has never made a secret of its goal to build a better Botox. The Newark, Calif.-based company is making swift progress to reach that target as it prepares to file a BLA for lead program RT-002, an injectable formulation of daxibotulinumtoxinA, in moderate to severe glabellar lines after moving RT-002 into a pivotal phase III to treat cervical dystonia.
Read More

GSK takes Tesaro for $5.1B, adds Zejula and I-O prospects to pipeline

Dec. 4, 2018
By Marie Powers
With Zejula (niraparib) well on its way to blockbuster status, Glaxosmithkline plc (GSK) paid a premium for the opportunity to pick up developer Tesaro Inc. in a deal valued at approximately $5.1 billion. But while Tesaro shares (NASDAQ:TSRO) spiked nearly to the proposed price of $75 per share – a 62 percent premium to Friday's closing price of $46.38 and a 110 percent premium to Tesaro's 30-day volume-weighted average price of $35.67 – GSK investors gave the transaction a chilly reception, pushing the stock (NYSE:GSK) down 7.8 percent to close at $38.61 for a loss of $3.26.
Read More

On eve of ASH, Fate and FDA reach accord on first IND for iPSC cell line

Dec. 3, 2018
By Marie Powers
As participants descended on San Diego for the American Society of Hematology (ASH) annual meeting, Fate Therapeutics Inc. prefaced its presentations with the disclosure that the FDA authorized its IND for FT-500, a universal, off-the-shelf natural killer (NK) cell product candidate derived from a clonal master induced pluripotent stem cell (iPSC) line. FT-500 is expected to be the first iPSC-derived cell product to move into the clinic in the U.S., and prospects for manufacturing from a single master pluripotent cell line "could revolutionize cell therapy," wrote Piper Jaffray's Edward Tenthoff in a hot comment.
Read More

Catalyst clears 'overhang' as Firdapse gains first FDA approval in LEMS

Nov. 30, 2018
By Marie Powers
Catalyst Pharmaceuticals Inc. turned the commercial corner with FDA approval, on its PDUFA date, of Firdapse (amifampridine phosphate) 10-mg tablets as the first drug designated in the U.S. to treat adults with Lambert-Eaton myasthenic syndrome (LEMS).
Read More
View All Articles by Marie Powers

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 23, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 23, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 20, 2025
  • Drug capsule and dollar sign

    Little bite from voluntary most-favored nation Rx pricing order

    BioWorld
    After a week of hype, the most-favored nation (MFN) drug pricing executive order (EO) U.S. President Donald Trump signed May 12 has a lot of bark but little bite,...
  • Illustration of liver with DNA double helixes

    ASGCT 2025: Gene and cell therapies transform metabolic diseases

    BioWorld Science
    Metabolic disorders such as argininosuccinic and glutaric aciduria, methylmalonic acidemia, homocystinuria or primary hyperoxaluria require specific diets to...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe